TY - JOUR

T1 - Synthesis of closo- and nido-carborane derivatives of the KRGD peptide

AU - Gruzdev, Dmitry A.

AU - Vakhrushev, Alexander V.

AU - Demin, Alexander M.

AU - Baryshnikova, Maria A.

AU - Levit, Galina L.

AU - Krasnov, Victor P.

AU - Charushin, Valery N.

N1 - The work was financially supported by the Russian Science Foundation (grant 21-73-10073) (in part of compounds synthesis) and by the Ministry of Science and Higher Education of Russian Federation (theme no. 124020200038-6) (in part of cytotoxicity assessment). Equipment of the Center for Joint Use “Spectroscopy and Analysis of Organic Compounds” at the Postovsky Institute of Organic Synthesis of the Russian Academy of Sciences (Ural Branch) was used. Autors are grateful to Dr. O.S. Eltsov for his assistance in registration of NMR spectra.

PY - 2024/3/1

Y1 - 2024/3/1

N2 - Peptides of the RGD family are of significant interest as vectors for targeted delivery of various therapeutic and diagnostic groups to tumor cells. Their application can be especially useful in the implementation of boron neutron capture therapy (BNCT) of malignant tumors. We have developed a method for obtaining derivatives of the lysine–arginine–glycine–aspartic acid (KRGD) peptide containing two closo‑ or nido‑carborane fragments linked to a lysine residue. It has been shown that to obtain bis(closo‑carboranyl) KRGD peptide with free functional groups, it is preferable to use protecting groups that can be removed under mild acidic conditions. Deboronation of the peptide containing closo‑carborane residues made it possible to obtain a bis(nido‑carboranyl) tetrapeptide containing 20 wt.% boron and having high solubility in water (up to 5 mg/mL). In vitro experiments demonstrated the low cytotoxicity of the KRGD peptide containing two nido‑carborane residues (CC50 > 100 μmol/L). The developed synthetic approach to KRGD derivatives containing 18–20 boron atoms per molecule opens the way to potential boron delivery agents for BNCT.

AB - Peptides of the RGD family are of significant interest as vectors for targeted delivery of various therapeutic and diagnostic groups to tumor cells. Their application can be especially useful in the implementation of boron neutron capture therapy (BNCT) of malignant tumors. We have developed a method for obtaining derivatives of the lysine–arginine–glycine–aspartic acid (KRGD) peptide containing two closo‑ or nido‑carborane fragments linked to a lysine residue. It has been shown that to obtain bis(closo‑carboranyl) KRGD peptide with free functional groups, it is preferable to use protecting groups that can be removed under mild acidic conditions. Deboronation of the peptide containing closo‑carborane residues made it possible to obtain a bis(nido‑carboranyl) tetrapeptide containing 20 wt.% boron and having high solubility in water (up to 5 mg/mL). In vitro experiments demonstrated the low cytotoxicity of the KRGD peptide containing two nido‑carborane residues (CC50 > 100 μmol/L). The developed synthetic approach to KRGD derivatives containing 18–20 boron atoms per molecule opens the way to potential boron delivery agents for BNCT.

UR - http://www.scopus.com/inward/record.url?partnerID=8YFLogxK&scp=85185198553

UR - https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=tsmetrics&SrcApp=tsm_test&DestApp=WOS_CPL&DestLinkType=FullRecord&KeyUT=001188135500001

U2 - 10.1016/j.jorganchem.2024.123052

DO - 10.1016/j.jorganchem.2024.123052

M3 - Article

VL - 1008

JO - Journal of Organometallic Chemistry

JF - Journal of Organometallic Chemistry

SN - 0022-328X

M1 - 123052

ER -